---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-226404"
form_type: "8-K"
ticker: null
cik: "0001538210"
company_name: "NexImmune, Inc."
filed_at: "2023-08-31T23:59:59+00:00"
generated_at: "2026-06-11T01:10:09.769451+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NexImmune cuts workforce 53%, CFO departs; expects $2.3M in severance costs

## Summary
- Workforce reduced from 47 to 22 employees (~53% cut) effective September 5, 2023.
- Estimated $2.3 million in severance and termination costs, primarily in Q3 fiscal 2023.
- CFO John Trainer employment ends September 2; he will transition to consulting role.
- VP Corporate Controller Timothy Stover appointed new Principal Financial and Accounting Officer.

## SEC filing metadata
- accession: 0001193125-23-226404
- form_type: 8-K
- cik: 0001538210
- company_name: NexImmune, Inc.
- filed_at: 2023-08-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1538210/000119312523226404/0001193125-23-226404-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1538210/000119312523226404/d689875d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-226404
- JSON: https://secwatch.observer/filing/0001193125-23-226404.json
- Plain text: https://secwatch.observer/filing/0001193125-23-226404.txt

## Key facts
- Executive change
  John Trainer was terminated as Chief Financial Officer and Principal Financial and Accounting Officer at NexImmune, Inc..
  - Action: terminated
  - Role: Chief Financial Officer and Principal Financial and Accounting Officer
  source text: the Company and John Trainer, the Company’s Chief Financial Officer and the Company’s Principal Financial and Accounting Officer, agreed on August 30, 2023 that Mr. Trainer’s employment with the Company will terminate effective as of September 2, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1538210/000119312523226404/0001193125-23-226404-index.htm
- Executive change
  Timothy Stover was appointed as Principal Financial and Accounting Officer at NexImmune, Inc..
  - Action: appointed
  - Role: Principal Financial and Accounting Officer
  source text: On August 30 2023, Timothy Stover, the Company’s Vice President, Corporate Controller, was appointed the Principal Financial and Accounting Officer of the Company effective as of September 2, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1538210/000119312523226404/0001193125-23-226404-index.htm
- Restructurings & Charges
  NexImmune, Inc. announced a restructuring with charges of approximately 53% reduction in workforce affecting workforce (reduction in workforce from 47 to 22 full-time employees as of September 5, 2023).
  - Type: restructuring
  - Charge: approximately 53% reduction in workforce
  - Affected area: workforce
  - Headcount: reduction in workforce from 47 to 22 full-time employees as of September 5, 2023
  source text: On August 31, 2023, NexImmune, Inc. (the “Company”) announced that, in order to reduce its cash expenditures while continuing to pursue its existing strategic plan, its Board of Directors approved and its management is implementing an approximately 53% reduction in workforce, designed to reduce costs and extend the Company’s cash. The realignment would reduce the Company’s workforce from 47 to 22 full-time employees as of September 5, 2023. The Company estimates that it will incur approximately $2.3 million of costs in connection with the reduction in workforce related to severance pay and other related termination benefits. The Company may incur one-time cash costs associated with the termination of certain contracts under the workforce reduction, and is in the process of assessing the estimated impact. The Company communicated the workforce reduction on August 31, 2023 and expects the majority of the costs associated with the reduction to be incurred during the third quarter ending S
  evidence_url: https://www.sec.gov/Archives/edgar/data/1538210/000119312523226404/0001193125-23-226404-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.